Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
iDose TR uses Celanese's (CE) VitalDose EVA. It is approved following the completion of two pivotal trials which demonstrates safety and efficacy.